Physician profile
Mark J Kranis
NPI 1548217920
$10,827.99
in general payments reported to CMS, 2019-2025
32 companies · $2,315 in 2025
The $2,315 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,178 · 2020: $661 · 2021: $1,069 · 2022: $1,528 · 2023: $1,830 · 2024: $2,247 · 2025: $2,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,392.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,356.42 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,232.58 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $969.74 | 2019-2025 | |
| Pfizer INC. | $952.12 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $949.91 | 2019-2025 | Camzyos, Eliquis |
| Abiomed | $785.68 | 2022-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $769.71 | 2019-2025 | Jardiance |
| Lantheus Medical Imaging, INC. | $507.04 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $469.79 | 2019-2025 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $436.25 | 2021-2025 | Uptravi, Opsumit |
| Medtronic, INC. | $377.22 | 2021-2025 | Micra, Azure Xt Dr Mri Surescan, Linq II |
| Boston Scientific Corporation | $290.55 | 2021-2025 | Watchman Flx, Accolade Sr |
| Janssen Pharmaceuticals, INC | $287.68 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $186.20 | 2025 | Onpattro, Amvuttra |
| Medtronic Vascular, INC. | $174.16 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $166.69 | 2025 | Cardiomems, Mitraclip, Amplatzer |
| Scpharmaceuticals INC. | $151.83 | 2023-2025 | |
| Amarin Pharma, INC. | $150.38 | 2019-2021 | |
| Heartflow, INC. | $147.26 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $89.75 | 2024 | Arcalyst |
| Bardy Diagnostics, INC. | $80.00 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $57.85 | 2024 | |
| Esperion Therapeutics, INC. | $35.99 | 2023-2024 | Nexletol |
| Alexion Pharmaceuticals, INC. | $34.05 | 2021 | |
| Sanofi-Aventis U.S. LLC | $33.78 | 2019-2020 | |
| Bridgebio Pharma, INC. | $28.80 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $24.98 | 2021 | |
| Ge Healthcare | $20.41 | 2021 | |
| Incyte Corporation | $19.26 | 2021 | |
| Astellas Pharma US INC | $15.42 | 2020 | |
| Novo Nordisk INC | $14.21 | 2023 | Rybelsus, Ozempic |
| Cvrx, INC. | $12.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kranis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.